On Friday, Shares of Exelon Corporation (NYSE:EXC), gained 2.86% to $34.50.
Exelon Corporation, and Pepco Holdings Inc. (POM) issued the following statement in response to the Maryland Public Service Commission’s decision on their merger.
“We are happy that the Maryland Public Service Commission has approved our merger. However, the Commission’s order modifies a number of the projected conditions and we must carefully review it in its entirety. Our proposal delivers noteworthy economic benefits to Maryland customers, enhances reliability, promotes energy efficiency and advances clean energy as part of a long-term commitment to improve service and modernize our grid. We will have more to say once we have time to study the order.”
Exelon Corporation, a utility services holding company, engages in the energy generation and delivery businesses in the United States. It owns electric generating facilities, such as nuclear, fossil, and hydroelectric generation facilities, in addition to wind and solar photovoltaic facilities.
Shares of Sanofi (NYSE:SNY), declined -0.53% to $50.52, during its last trading session.
Sanofi, declared that, under the terms of an existing planned global collaboration, Sanofi, has exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease.
In celiac disease patients, the consumption of gluten-containing food induces harmful immune responses that can lead to abdominal pain and, in most severe cases, intestinal cancer. This new immune tolerance program expands activities within the Sanofi-Selecta collaboration, which is already successfully advancing a novel immunotherapy for a life-threatening food allergy. The products resulting from this partnership will leverage Selecta’s proprietary Synthetic Vaccine Particle (SVP™) platform, which has unique capabilities to engineer nanoparticles with the structure and composition to produce immune tolerance by attenuating the overactive response to specific antigens.
Under the terms of the collaboration, Selecta is eligible to receive research support and several pre-clinical, clinical, regulatory and sales milestones totaling up to $300 million for this new program in celiac disease. Additionally, Selecta is also entitled to up to double digit tiered royalties as percentage of product net sales for any commercialized immunotherapy resulting from these efforts with Sanofi.
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
At the end of Friday’s trade, Shares of Umpqua Holdings Corporation (NASDAQ:UMPQ), lost -1.06% to $17.22.
Ron Farnsworth, executive vice president and chief financial officer for Umpqua Holdings Corporation, and its auxiliaries, Umpqua Bank and Umpqua Investments, was recently named CFO of the Year in the public company category by the Portland Business Journal. Farnsworth was formerly honored with the award in 2010.
As CFO, Farnsworth oversees all aspects of Umpqua’s financial and fiscal operations in addition to the company’s technology division. Farnsworth was promoted to the position of CFO in 2008 in the middle of the country’s most challenging financial environments. Under Farnsworth’s leadership, Umpqua emerged from the Great Recession with a balance sheet even stronger than it was before the crisis began.
Farnsworth was instrumental in Umpqua’s 2014 acquisition of Sterling Financial, which doubled the company’s size and footprint to about $23 billion in assets, $15 billion in loans and $16 billion in deposits, with more than 4,500 associates and 350 stores across five states - Oregon, Washington, Idaho, California and Nevada.
The CFO of the Year Awards is an annual event hosted by Portland Business Journal to recognize the region’s top financial stewards.
Umpqua Holdings Corporation, through its auxiliaries, engages in the commercial and retail banking, and retail brokerage businesses. It operates through two segments, Community Banking and Home Lending. The Community Banking segment provides loan and deposit products to business and retail customers.
Finally, Freescale Semiconductor, Ltd. (NYSE:FSL), ended its last trade with 0.36% gain, and closed at $41.59.
Freescale Semiconductor, introduced its Intelligent Sensing Framework (ISF) 2.1, which now comprises integration with Freescale’s Processor Expert tool to assist create, configure, and generate embedded sensor-based applications for Freescale microcontrollers (MCUs). This integration, together with the framework’s sensor fusion functionality and expanded support for additional sensor types, speeds and simplifies the development of sensor-based solutions for the Internet of Tomorrow – from the connected home and wearables to new medical and connected industrial applications.
A large portion of new, sensor-based Internet of Things (IoT) solutions originate from startup organizations often unfamiliar with the complex process of abstracting, combining and using sensor data. As sensors become increasingly critical to the success of IoT applications, embedded developers need to find ways to quickly and easily integrate multiple streams of sensor data with the MCUs powering their applications.
Freescale Semiconductor, Ltd. provides embedded processors worldwide. The company’s products comprise microcontrollers, ranging from 8-bit products to higher performance 16-bit and 32-bit products with on-board flash memory, which provide the digital logic or intelligence for electronic applications and controlling electronic equipment or analyzing sensor inputs; single-and multi-core microprocessors; and applications processors with embedded memory, and special purpose hardware and software for multimedia applications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
